SNT 2.44% 4.2¢ syntara limited

Ann: FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study, page-3

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 328 Posts.
    lightbulb Created with Sketch. 52
    Wow... the potential of this is huge.
    If I understand this ...they are talking about increase of efficacy of existing treatments, so we could license this to every single chemo drug manufacturer for treatment of targeted cancers?
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
(20min delay)
Last
4.2¢
Change
0.001(2.44%)
Mkt cap ! $57.67M
Open High Low Value Volume
4.2¢ 4.2¢ 4.0¢ $16.80K 409.7K

Buyers (Bids)

No. Vol. Price($)
2 582773 4.0¢
 

Sellers (Offers)

Price($) Vol. No.
4.2¢ 206073 2
View Market Depth
Last trade - 16.10pm 01/11/2024 (20 minute delay) ?
SNT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.